- Dec 20, 2017

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

Fusion oncoprotein forces cell fates toward rhabdomyosarcoma

“DNA loops” in pediatric brain tumors double relapse risk

Radiation from a childhood CT scan increases the risk of developing cancer

Childhood Leukemia Linked to Pesticides Used in Vineyards

FDA Gives Priority Review to Tovorafenib in Pediatric Low-Grade Glioma

NIH researchers develop approach that could help supercharge T-cell therapies against solid tumors

Cranial Radiotherapy Predisposes Pediatric Cancer Survivors to Hypothyroidism

Examining outcomes in children with Down syndrome and acute lymphoblastic leukemia

Impact of childhood and adolescence cancer on family caregivers

Collaborative study identifies potential targets to treat the most common childhood liver cancer

Recent Posts

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

Archive

Search By Tags